每周一次艾塞那肽对2型糖尿病心血管结局的影响
EXSCEL试验将14,752例2型糖尿病(73.1%有心血管病史)随机分配至每周一次皮下注射艾塞那肽2 mg或安慰剂,中位随访3.2年。主要复合终点(心血管死亡、非致死性心肌梗死或非致死性卒中)在艾塞那肽组发生839/7356例(11.4%,3.7事件/100人年),安慰剂组905/7396例(12.2%,4.0事件/100人年),HR 0.91(95%CI 0.83–1.00)。艾塞那肽在安全性方面非劣效于安慰剂(P<0.001),但在疗效方面未优于安慰剂(P=0.06)。心血管死亡、致死或非致死性心肌梗死、致死或非致死性卒中、心力衰竭住院、急性冠脉综合征住院、急性胰腺炎、胰腺癌、甲状腺髓样癌及严重不良事件发生率两组无显著差异。
要点
- 在2型糖尿病伴或不伴心血管病史患者中,每周一次艾塞那肽2 mg皮下注射的主要不良心血管事件发生率为11.4%(839/7356),安慰剂组为12.2%(905/7396),HR 0.91(95%CI 0.83–1.00)。
- 艾塞那肽在安全性方面非劣效于安慰剂(P<0.001),但在疗效(主要复合终点)方面未优于安慰剂(P=0.06)。
- 心血管死亡、致死或非致死性心肌梗死、致死或非致死性卒中、心力衰竭住院、急性冠脉综合征住院发生率两组无显著差异。
- 急性胰腺炎、胰腺癌、甲状腺髓样癌及严重不良事件发生率两组无显著差异。
- 中位随访3.2年(四分位距2.2–4.4年),73.1%(10,782/14,752)患者有既往心血管疾病。
适用人群与场景
- 2型糖尿病患者,伴或不伴既往心血管疾病;共14,752例,其中10,782例(73.1%)有既往心血管疾病。
处置流程与药物剂量
- 艾塞那肽组:每周一次皮下注射缓释艾塞那肽2 mg。
- 对照组:每周一次皮下注射匹配安慰剂。
研究设计与关键结果
- 研究类型:随机对照试验(EXSCEL,NCT01144338),14,752例2型糖尿病患者,随机分配至每周一次皮下注射艾塞那肽2 mg(7356例)或安慰剂(7396例),中位随访3.2年(四分位距2.2–4.4年)。
- 主要复合终点(心血管死亡、非致死性心肌梗死或非致死性卒中的首次发生):艾塞那肽组839/7356例(11.4%,3.7事件/100人年)vs 安慰剂组905/7396例(12.2%,4.0事件/100人年),HR 0.91(95%CI 0.83–1.00)。
- 安全性非劣效检验:P<0.001(非劣效);疗效优效性检验:P=0.06(未优于安慰剂)。
- 心血管死亡、致死或非致死性心肌梗死、致死或非致死性卒中、心力衰竭住院、急性冠脉综合征住院发生率两组无显著差异。
- 急性胰腺炎、胰腺癌、甲状腺髓样癌及严重不良事件发生率两组无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在2型糖尿病伴或不伴心血管病患者中,每周一次艾塞那肽2 mg皮下注射未显著降低主要不良心血管事件发生率(HR 0.91,95%CI 0.83–1.00),安全性非劣效于安慰剂。
- 原文结论:艾塞那肽组与安慰剂组主要不良心血管事件发生率无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy.
RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups.
CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .).
参考来源
- Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017. PMID: 28910237. doi:10.1056/NEJMoa1612917
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。